Local Control and survival
The median follow-up for all investigated patients was 85 months (range 47.9-124.2). A total of 23 failures were observed. Recurrence in the primary tumor site occurred in 10 patients. In addition, 2 patients had recurrence in the pelvic lymph nodes, 13 patients had distant metastases alone.
For all investigated patients, the local recurrence free survival rate at 5 years was 87.6%, metastasis recurrence-free survival at 5 years was 82.4%, respectively. The estimated overall actuarial cancer specific survival rate at 5 years was 76.3%, respectively. Moreover, 5 years disease free survival rate was 70.9%, respectively. Analysis of survival according to FIGO stage is shown in Figure 2 and table S1-4.